iMMURACAccredidationReleaseFINAL

iMMURACAccredidationReleaseFINAL

• 1.
  NEWS RELEASE FOR IMMEDIATERELEASE Contact: Laci Foster inVentiv Medical Management +1 706 855 0830 x2280 [email protected] inVentiv Medical Management Receives Two More Accreditations in Population Health Management iMM Helps Providers Enter New Era of Value-Based Care by Providing Comprehensive, Quality Services that Improve Outcomes CHARLOTTE, N.C. – August 1, 2013 – inVentiv Health Medical Management (iMM) announced today that it has become part of a select group of companies receiving three accreditations in Population Health Management (PHM) from a national organization setting quality standards for U.S. healthcare. PHM has become a centerpiece in improving patient outcomes under the Affordable Care Act. iMM received the three accreditations from URAC, the nation’s largest accrediting body for PHM. Under the federal Affordable Care Act providers are rewarded for the value of the care they deliver to patients rather than the volume of care. Providers must deliver improved outcomes at lower costs. PHM helps deliver evidence-based, coordinated care across the healthcare continuum, from promoting wellness to managing complex chronic diseases. “As providers sprint to meet the federal requirements under the Affordable Care Act, they can turn to us as their single source for management of population health,” said Marc Palmer, CEO of iMM. “For employers, human resources professionals and claims administrators, it is far easier to manage a single provider that they can count on for the highest quality services, rather than multiple providers.” iMM now holds accreditation in Health Utilization Management, Case Management and Disease Management services from URAC: • Health Utilization Management: The first accreditation from URAC, received in 2012, was for the independent, clinical evaluation of the appropriateness, medical need and efficient use of healthcare services according to evidence-based guidelines and individual health plan benefits. • Case Management: One of the two most recent accreditations, effective July 1, recognizes the quality of iMM’s collaborative care process between a consumer, care providers and clinical case managers toward the goal of promoting cost-effective outcomes and a return to health. • Disease Management: The second of the most recent accreditations, this one recognizes the high quality of iMM’s delivery and coordination of health interventions over the long term by nurses who help consumers reduce the financial, emotional and physical burdens of chronic disease. “By applying for and receiving Case Management and Disease Management accreditation, inVentiv Medical Management has demonstrated a commitment to quality healthcare,” said URAC Chief Operating Officer William Vandervennet. “Quality healthcare is crucial to our nation’s welfare and it is important to have organizations that are willing to measure
• 2.
  NEWS RELEASE themselves againstnational standards and undergo rigorous evaluation by an independent accrediting body.” iMM employs an in-house medical team of physicians and nurses, as well as dieticians and social workers, to manage care. These experts tap a proprietary database, the inFinitē Platform, which enables predictive modeling to inform the coordinated care of individual patients. iMM delivers services appropriate to the individual, while eliminating gaps in care, promoting cost effectiveness and creating a seamless experience for consumers. iMM programs that combine the three accredited services have already shown measurable success in improving outcomes for patients suffering from some of the most complex, costly diseases, such as cancer, cardiovascular disease and chronic kidney disease. About URAC URAC, an independent, nonprofit organization, is a leader in promoting health care quality through accreditation and certification programs. URAC's standards keep pace with the rapid changes in the healthcare system, and provide a mark of distinction for healthcare organizations to demonstrate their commitment to quality and accountability. Through its broad-based governance structure and an inclusive standards development process, URAC ensures that all stakeholders are represented in setting meaningful standards for the healthcare industry. For more information, visit www.urac.org. About inVentiv Medical Management inVentiv Medical Management, an inVentiv Health company, is a leading national provider of physician-directed, nurse-supported, technology-enabled, population health management solutions to third party administrators, self-funded and fully insured plans, employer groups, Accountable Care Organizations (ACOs) and health plans. With a mission of improving healthcare quality, costs and outcomes, enabled by the fully integrated inFinitē Platform inVentiv Medical Management delivers seamless clinical interventions and cost management that support consumers, providers and payers. inVentiv Medical Management is headquartered in Charlotte, North Carolina. Please visit http://www.inVentivMM.com for more information. About inVentiv Health inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv offers convergent services that deliver extraordinary outcomes to clients whose goal is improving human life. In 40 countries around the world, inVentiv’s 13,000 employees help clients rapidly transform promising ideas into commercial reality. inVentiv clients include more than 550 pharmaceutical, biotech and life sciences companies, as well as companies that now see health as part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inVentivHealth.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital
• 3.
  NEWS RELEASE expenditures topermit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors. # # #